Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial
Introduction
There are no determined treatment agents for severe COVID-19. It is suggested that methylprednisolone, as an immunosuppressive treatment, can reduce the inflammation of the respiratory system in COVID-19 patients.
Methods
We conducted a single-blind, randomised controlled clinical trial involving severe hospitalised patients with confirmed COVID-19 at the early pulmonary phase of the illness in Iran. The patients were randomly allocated in a 1:1 ratio by the block randomisation method to receive standard care with methylprednisolone pulse (intravenous injection, 250 mg·day−1 for 3 days) or standard care alone. The study end-point was the time of clinical improvement or death, whichever came first. Primary and safety analysis was done in the intention-to-treat (ITT) population.
Results
68 eligible patients underwent randomisation (34 patients in each group) from April 20, 2020 to June 20, 2020. In the standard care group, six patients received corticosteroids by the attending physician before the treatment and were excluded from the overall analysis. The percentage of improved patients was higher in the methylprednisolone group than in the standard care group (94.1% versus 57.1%) and the mortality rate was significantly lower in the methylprednisolone group (5.9% versus 42.9%; p<0.001). We demonstrated that patients in the methylprednisolone group had a significantly increased survival time compared with patients in the standard care group (log-rank test: p<0.001; hazard ratio 0.293, 95% CI 0.154–0.556). Two patients (5.8%) in the methylprednisolone group and two patients (7.1%) in the standard care group showed severe adverse events between initiation of treatment and the end of the study.
Conclusions
Our results suggest that methylprednisolone pulse could be an efficient therapeutic agent for hospitalised severe COVID-19 patients at the pulmonary phase.
Top-30
Journals
|
1
2
3
4
5
6
7
8
|
|
|
European Respiratory Journal
8 publications, 2.87%
|
|
|
PLoS ONE
7 publications, 2.51%
|
|
|
Journal of Medical Virology
6 publications, 2.15%
|
|
|
Journal of Clinical Medicine
5 publications, 1.79%
|
|
|
Frontiers in Medicine
5 publications, 1.79%
|
|
|
BMC Infectious Diseases
5 publications, 1.79%
|
|
|
Infectious Diseases and Therapy
5 publications, 1.79%
|
|
|
Frontiers in Immunology
4 publications, 1.43%
|
|
|
Expert Review of Respiratory Medicine
4 publications, 1.43%
|
|
|
Medicine (United States)
4 publications, 1.43%
|
|
|
Viruses
4 publications, 1.43%
|
|
|
Scientific Reports
4 publications, 1.43%
|
|
|
BMC Pulmonary Medicine
4 publications, 1.43%
|
|
|
Cureus
4 publications, 1.43%
|
|
|
Acute Medicine & Surgery
4 publications, 1.43%
|
|
|
Virology Journal
3 publications, 1.08%
|
|
|
Infectious Diseases in Clinical Practice
3 publications, 1.08%
|
|
|
Pharmaceuticals
3 publications, 1.08%
|
|
|
Frontiers in Public Health
3 publications, 1.08%
|
|
|
Frontiers in Pharmacology
3 publications, 1.08%
|
|
|
Pharmacological Research
3 publications, 1.08%
|
|
|
International Immunopharmacology
3 publications, 1.08%
|
|
|
Meditsinskiy sovet = Medical Council
3 publications, 1.08%
|
|
|
Medical alphabet
3 publications, 1.08%
|
|
|
European Respiratory Review
2 publications, 0.72%
|
|
|
Monaldi Archives for Chest Disease
2 publications, 0.72%
|
|
|
Journal of Personalized Medicine
2 publications, 0.72%
|
|
|
COVID
2 publications, 0.72%
|
|
|
Infection
2 publications, 0.72%
|
|
|
1
2
3
4
5
6
7
8
|
Publishers
|
5
10
15
20
25
30
35
40
45
50
|
|
|
Springer Nature
46 publications, 16.49%
|
|
|
Elsevier
42 publications, 15.05%
|
|
|
MDPI
26 publications, 9.32%
|
|
|
Wiley
23 publications, 8.24%
|
|
|
Frontiers Media S.A.
17 publications, 6.09%
|
|
|
Taylor & Francis
15 publications, 5.38%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
14 publications, 5.02%
|
|
|
European Respiratory Society (ERS)
11 publications, 3.94%
|
|
|
Cold Spring Harbor Laboratory
8 publications, 2.87%
|
|
|
SAGE
7 publications, 2.51%
|
|
|
Public Library of Science (PLoS)
7 publications, 2.51%
|
|
|
Bentham Science Publishers Ltd.
4 publications, 1.43%
|
|
|
Hindawi Limited
4 publications, 1.43%
|
|
|
Oxford University Press
3 publications, 1.08%
|
|
|
BMJ
3 publications, 1.08%
|
|
|
Edizioni Minerva Medica
3 publications, 1.08%
|
|
|
Remedium, Ltd.
3 publications, 1.08%
|
|
|
Alfmed LLC
3 publications, 1.08%
|
|
|
Baishideng Publishing Group
2 publications, 0.72%
|
|
|
PAGEPress Publications
2 publications, 0.72%
|
|
|
American Medical Association (AMA)
2 publications, 0.72%
|
|
|
Eco-Vector LLC
2 publications, 0.72%
|
|
|
AME Publishing Company
2 publications, 0.72%
|
|
|
Japanese Society of Intensive Care Medicine
2 publications, 0.72%
|
|
|
American Thoracic Society
1 publication, 0.36%
|
|
|
S. Karger AG
1 publication, 0.36%
|
|
|
Spandidos Publications
1 publication, 0.36%
|
|
|
Japanese Society of Internal Medicine
1 publication, 0.36%
|
|
|
International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)
1 publication, 0.36%
|
|
|
5
10
15
20
25
30
35
40
45
50
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.